Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4019 | pregnant women with laboratory-confirmed 2019-n-CoV Wiki | 0.71 |
drug1437 | Heparin Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D014777 | Virus Diseases NIH | 0.10 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to recovery compared to heparin in hospitalized patients with COVID-19 and elevated D-dimer levels.
Description: central lab D-dimer results
Measure: Change in D-dimer level from Baseline to Day 8 (Phase 2b) Time: 8 daysDescription: clinical events as reported by site
Measure: Number of major or non-major clinically relevant bleeding events within thirty (30) days of randomization (Phase 2b) Time: 30 daysDescription: scale as assessed by investigator and clinical adjudication committee
Measure: Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3) Time: 30 daysDescription: central lab D-dimer results
Measure: Change in D-dimer level from baseline to Day 10 (Phase 2b) Time: 10 daysDescription: clinical events as reported by site
Measure: Number of major or non-major clinically relevant bleeding events with rNAPc2 vs. heparin (Phase 2b and 3) Time: 30 daysDescription: clinical events as reported by site
Measure: Number of bleeding events in subjects treated with higher vs. lower dose rNAPc2 at Day 10 (Phase 2b) Time: 10 daysDescription: clinical events as reported by site
Measure: Time to first occurrence of a composite of thrombotic events and all-cause mortality within thirty (30) days of randomization (Phase 3 only) Time: 30 daysDescription: clinical events as reported by site
Measure: Time to first occurrence of thrombotic events within thirty (30) days of randomization (Phase 3 only) Time: 30 daysDescription: clinical events as reported by site
Measure: Time to all-cause mortality within thirty (30) days of randomization (Phase 3 only) Time: 30 daysDescription: central lab samples collected per protocol
Measure: Change in Tissue Factor laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b) Time: day 8 and day 10Description: central lab samples collected per protocol
Measure: Change in interleukin-6 laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b) Time: day 8 and day 10Description: central lab samples collected per protocol
Measure: Change in high sensitivity C-reactive protein laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline to Days 8 and 10 (Phase 2b) Time: day 8 and day 10Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports